Institut de Medicina Predictiva i Personalitzada del Càncer, Badalona, Barcelona, Spain.
Hum Mutat. 2011 Jan;32(1):78-90. doi: 10.1002/humu.21387.
Dermal neurofibromas (dNFs) are benign tumors of the peripheral nervous system typically associated with Neurofibromatosis type 1 (NF1) patients. Genes controlling the integrity of the DNA are likely to influence the number of neurofibromas developed because dNFs are caused by somatic mutational inactivation of the NF1 gene, frequently evidenced by loss of heterozygosity (LOH). We performed a comprehensive analysis of the prevalence and mechanisms of LOH in dNFs. Our study included 518 dNFs from 113 patients. LOH was detected in 25% of the dNFs (N = 129). The most frequent mechanism causing LOH was mitotic recombination, which was observed in 62% of LOH-tumors (N = 80), and which does not reduce the number of NF1 gene copies. All events were generated by a single crossover located between the centromere and the NF1 gene, resulting in isodisomy of 17q. LOH due to the loss of the NF1 gene accounted for a 38% of dNFs with LOH (N = 49), with deletions ranging in size from ∼80 kb to ∼8 Mb within 17q. In one tumor we identified the first example of a neurofibroma-associated second-hit type-2 NF1 deletion. Analysis of the prevalence of mechanisms causing LOH in dNFs in individual patients (possibly under genetic control) will elucidate whether there exist interindividual variation.
皮肤神经纤维瘤(dNFs)是周围神经系统的良性肿瘤,通常与神经纤维瘤病 1 型(NF1)患者相关。控制 DNA 完整性的基因可能会影响神经纤维瘤的数量,因为 dNFs 是由 NF1 基因的体细胞突变失活引起的,通常表现为杂合性丢失(LOH)。我们对 dNFs 中 LOH 的流行情况和机制进行了全面分析。我们的研究包括 113 名患者的 518 个 dNFs。25%的 dNFs 存在 LOH(N = 129)。导致 LOH 的最常见机制是有丝分裂重组,在 62%的 LOH 肿瘤中观察到(N = 80),这不会减少 NF1 基因拷贝数。所有事件都是由位于着丝粒和 NF1 基因之间的单一交叉产生的,导致 17q 的同二倍体。由于 NF1 基因的丢失导致的 LOH 占 LOH 的 dNFs 的 38%(N = 49),LOH 大小从 17q 内的 80kb 到 8Mb 不等。在一个肿瘤中,我们鉴定了首例与神经纤维瘤相关的第二打击型 2 NF1 缺失。分析单个患者(可能受遗传控制)中导致 LOH 的机制的流行情况将阐明是否存在个体间的差异。
J Invest Dermatol. 2009-3
Genes Chromosomes Cancer. 2000-8
Biochem Biophys Res Commun. 1997-5-19
Genes Chromosomes Cancer. 2006-10
Trends Mol Med. 2025-4
Neuromolecular Med. 2024-7-2
Cell Rep Methods. 2024-5-20
Neurosci Bull. 2024-6
World J Clin Cases. 2022-7-16
JCO Precis Oncol. 2022-5
Front Mol Neurosci. 2022-1-4
Cell Stem Cell. 2009-5-8
Hum Mol Genet. 2009-8-1
Cytogenet Genome Res. 2008
J Invest Dermatol. 2009-3
Hum Mutat. 2008-8